Phase II study of XELIRI with bevacizumab as second-line therapy for metastatic colorectal cancer -Beyond Progression Disease of capecitabine and bebacizumab -
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: Bevacizumab (7.5mg/kg) and CPT-11(200mg/m2) is administered on day1, and capecitabine (1600mg/m2) is administered from day 1 to day 14 Primary outcome(s): response rate Study Design: Single arm Non-randomized
创建时间：
2011-08-15
